Sales on 3q2013 were 183m in Us and 76m on rest of world (259m total)
Sales on 2q2013 were 178m in US and 81m on rest of world (259m total)
Sales on 3q2012 were 172m in US and 71m on rest of world (243m total)
So, basically sales were flat over 2Q13 and up 7% on 3q12
On 2q13 Npsp reported earning of 29m from sensipar royalties (but with a positive impact of 2M retrospective adjustment) and so the net was 27M.
With the numbers provided from Amgen sales royalties for NPSP will be around 26M (slightly lower respect of 2Q13)